Cloretazine for the treatment of acute myeloid leukemia

Norbert Vey*, Frank Giles

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Cloretazine is a new sulfonylhydrazine alkylating agent with antileukemic activity. Phase I studies have shown myelosuppression to be the dose limiting toxicity in both solid tumors and leukemias. A large Phase II study of single agent cloretazine (600 mg/m2) confirmed its activity in patients with relapsed acute myeloid leukemia, and in elderly patients with previously untreated acute myeloid leukemia or myelodysplastic syndrome. It also confirmed the limited nonhematological toxicity, even in elderly patients. Cloretazine can be safely combined with cytarabine, and this combination regimen is currently being tested in a large Phase III study in patients with relapsed acute myeloid leukemia. Cloretazine is a promising new antileukemic agent that may be incorporated into an intensive combination regimen.

Original languageEnglish (US)
Pages (from-to)321-328
Number of pages8
JournalExpert review of anticancer therapy
Issue number3
StatePublished - Mar 1 2006


  • Acute myeloid leukemia
  • Alkylating agents
  • Cloretazine elderly
  • Induction chemotherapy
  • Myelodysplastic syndrome

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Cloretazine for the treatment of acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this